Literature DB >> 33867733

The Outcome of Acute Lymphoblastic Leukemia in 109 Adult Iraqi Patients.

Dyna Jaza Mohammed1, Sana Dlawar Jalal2, Ahmed Khudair Yassin3, Ali Ibrahim Mohammed2, Nasir Abdulsalam Al-Allawi4.   

Abstract

While many studies addressed the outcome of adult ALL in developed Western countries, there is paucity of such prospective studies from developing Mediterranean ones. This is a prospective cohort study conducted at Hiwa Cancer Hospital in Sulaimani city and Nanakali Hospital in Erbil city-Kurdistan Iraq from March 2012 to August 2017. The main characteristics of adult ALL patients, type of therapy and risk factors were analyzed to assess their impact on treatment outcome and survival status. A total of 109 adult ALL patients were included with a median age of 24 years and male to female ratio of 1.7:1. B-ALL accounted for 76.1% of the cases, while the rest were T-ALL. BCR-ABL rearrangement was encountered in 12% of B-ALL. Complete remission (CR) rate was 81.7%, the overall 5 year survival (OS) was 38%, Relapse Free 5 year Survival (RFS) was 49%. Younger adults (< 35 years) had significantly higher CR rates and OS compared to the older group (P < 0.001 each). On the other hand, gender, high leucocyte count ≥ 50×109/L, immunophenotype (including B and T ALL subtypes), and clinical risk status did not predict a poor outcome. Multivariate analysis revealed that only age < 35 years and BCR-ABL rearrangement were significantly associated with better OS. Despite some limitations, the outcomes of Iraqi adult ALL is comparable to those reported in Western developed countries, with particularly favorable outcomes in younger patients. The need to improve outcome in adult ALL remains an important priority in our country as it is throughout the world. © Indian Society of Hematology and Blood Transfusion 2020.

Entities:  

Keywords:  Acute lymphoblastic leukemia; Adults; Iraq; Outcome; Survival

Year:  2020        PMID: 33867733      PMCID: PMC8012463          DOI: 10.1007/s12288-020-01345-1

Source DB:  PubMed          Journal:  Indian J Hematol Blood Transfus        ISSN: 0971-4502            Impact factor:   0.900


  21 in total

1.  Outcome of adult patients with acute lymphoblastic leukaemia receiving the MRC UKALL XII protocol: a tertiary care centre experience.

Authors:  M U Shaikh; N Ali; S N Adil; M Khurshid
Journal:  Singapore Med J       Date:  2011-05       Impact factor: 1.858

2.  Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.

Authors:  Naval Daver; Deborah Thomas; Farhad Ravandi; Jorge Cortes; Rebecca Garris; Elias Jabbour; Guillermo Garcia-Manero; Gautam Borthakur; Tapan Kadia; Michael Rytting; Marina Konopleva; Hagop Kantarjian; Susan O'Brien
Journal:  Haematologica       Date:  2015-02-14       Impact factor: 9.941

Review 3.  Prognostic factors in adult acute lymphoblastic leukaemia.

Authors:  Jacob M Rowe
Journal:  Br J Haematol       Date:  2010-06-22       Impact factor: 6.998

4.  Long-term outcome of adult acute lymphoblastic leukemia in Lebanon: a single institution experience from the American University of Beirut.

Authors:  Khalil M Charafeddine; Hassan A Hatoum; Zaher K Otrock; Rami A Mahfouz; Ziad M Salem; Ali I Shamseddine; Ali T Taher; Nagi S El-Saghir; Ali Bazarbachi
Journal:  Hematol Oncol Stem Cell Ther       Date:  2009

5.  Clinico-biological features of 5202 patients with acute lymphoblastic leukemia enrolled in the Italian AIEOP and GIMEMA protocols and stratified in age cohorts.

Authors:  Sabina Chiaretti; Antonella Vitale; Gianni Cazzaniga; Sonia Maria Orlando; Daniela Silvestri; Paola Fazi; Maria Grazia Valsecchi; Loredana Elia; Anna Maria Testi; Francesca Mancini; Valentino Conter; Geertruy te Kronnie; Felicetto Ferrara; Francesco Di Raimondo; Alessandra Tedeschi; Giuseppe Fioritoni; Francesco Fabbiano; Giovanna Meloni; Giorgina Specchia; Giovanni Pizzolo; Franco Mandelli; Anna Guarini; Giuseppe Basso; Andrea Biondi; Robin Foà
Journal:  Haematologica       Date:  2013-05-28       Impact factor: 9.941

6.  Trends in survival after diagnosis with hematologic malignancy in adolescence or young adulthood in the United States, 1981-2005.

Authors:  Dianne Pulte; Adam Gondos; Hermann Brenner
Journal:  Cancer       Date:  2009-11-01       Impact factor: 6.860

Review 7.  Acute lymphoblastic leukemia: a comprehensive review and 2017 update.

Authors:  T Terwilliger; M Abdul-Hay
Journal:  Blood Cancer J       Date:  2017-06-30       Impact factor: 11.037

8.  Acute lymphoblastic leukemia experience: epidemiology and outcome of two different regimens.

Authors:  Salah Abbasi; Faten Maleha; Muhannad Shobaki
Journal:  Mediterr J Hematol Infect Dis       Date:  2013-04-10       Impact factor: 2.576

Review 9.  Management of older adults with acute lymphoblastic leukemia: challenges & current approaches.

Authors:  Yazeed Sawalha; Anjali S Advani
Journal:  Int J Hematol Oncol       Date:  2018-04-10

10.  Adult Acute Lymphoblastic Leukemia: Limitations of Intensification of Therapy in a Developing Country.

Authors:  Punit Jain; Anu Korula; Prashant Deshpande; Nisham Pn; Ansu Abu Alex; Aby Abraham; Alok Srivastava; Nancy Beryl Janet; Kavitha M Lakshmi; Poonkuzhali Balasubramanian; Biju George; Vikram Mathews
Journal:  J Glob Oncol       Date:  2018-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.